BioAge Labs (BIOA) Debt Ratio (2023 - 2026)

BioAge Labs (BIOA) reported Debt Ratio of 0.0 for Q1 2026, down 85.8% on a YoY basis from 0.02 in Q1 2025, and down 67.54% sequentially from 0.01 in Q4 2025.

BioAge Labs (BIOA) Debt Ratio (2023 - 2026) Analysis & Trends

BioAge Labs (BIOA) has 4 years of Debt Ratio data on file, last reported at 0.0 in Q1 2026.

  • For the quarter ending Q1 2026, Debt Ratio fell 85.8% year-over-year to 0.0; the trailing twelve-month figure through Mar 2026 stood at 0.0 (down 85.8% YoY), and the FY2025 full-year result was 0.01, down 62.16% from the prior year.
  • Debt Ratio declined to 0.0 in Q1 2026, from 0.01 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.55 in Q4 2023 to a low of 0.0 in Q1 2026.
  • A 4-year average of 0.08 and a median of 0.02 in 2025 frame the typical range for Debt Ratio.
  • Across the five-year window, Debt Ratio plunged 95.67% in 2024 and tumbled 54.1% in 2025, its largest moves.
  • Tracing BIOA's Debt Ratio over 4 years: stood at 0.55 in 2023, then sank by 95.67% to 0.02 in 2024, then sank by 62.16% to 0.01 in 2025, then tumbled by 67.54% to 0.0 in 2026.
  • Business Quant data shows BIOA's Debt Ratio at 0.0 in Q1 2026, 0.01 in Q4 2025, and 0.01 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 0.26
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 0.42
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 0.60
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 0.29
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 0.10
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 0.39
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 0.29
10 BioAge Labs 930.32 Mn 930.32 Mn -10.37 Mn 0.00

Historic Data

Download Data
DateValue
Mar 31, 2026 0.00
Dec 31, 2025 0.01
Sep 30, 2025 0.01
Jun 30, 2025 0.02
Mar 31, 2025 0.02
Dec 31, 2024 0.02
Sep 30, 2024 0.03
Dec 31, 2023 0.55